Fda Approved Bexarotene Reverses Alzheimer S Disease Deficits In Mice
An anti-cancer drug reverses memory deficits in an Alzheimer’s disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science. The research, funded by the National Institutes of Health’s National Institute on Aging and Alzheimer’s Association, reviewed previously published findings on the drug bexarotene, approved by the U.S. Food and Drug Administration for use in cutaneous T cell lymphoma. The Pitt Public Health researchers were able to verify that the drug does significantly improve cognitive deficits in mice expressing gene mutations linked to human Alzheimer’s disease, but could not confirm the effect on amyloid plaques....